MAVIK Drug Patent Profile
✉ Email this page to a colleague
When do Mavik patents expire, and what generic alternatives are available?
Mavik is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in MAVIK is trandolapril. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the trandolapril profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mavik
A generic version of MAVIK was approved as trandolapril by AUROBINDO PHARMA on June 12th, 2007.
Summary for MAVIK
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 75 |
| Patent Applications: | 4,558 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in MAVIK? | MAVIK excipients list |
| DailyMed Link: | MAVIK at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MAVIK
Paragraph IV (Patent) Challenges for MAVIK
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MAVIK | Tablets | trandolapril | 1 mg, 2 mg and 4 mg | 020528 | 1 | 2004-10-04 |
US Patents and Regulatory Information for MAVIK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-001 | Apr 26, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-002 | Apr 26, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-003 | Apr 26, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MAVIK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-003 | Apr 26, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-003 | Apr 26, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-001 | Apr 26, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-002 | Apr 26, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-001 | Apr 26, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | MAVIK | trandolapril | TABLET;ORAL | 020528-003 | Apr 26, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MAVIK
See the table below for patents covering MAVIK around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 67572 | TRANS-2-AZA BICYCLO(3.(3+N).O)ALKANE-3-CARBOXYLIC ACID DERIVATIVES,PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Try a Trial |
| Denmark | 171232 | ⤷ Try a Trial | |
| Hong Kong | 1006003 | ⤷ Try a Trial | |
| Germany | 3275293 | ⤷ Try a Trial | |
| Luxembourg | 88263 | ⤷ Try a Trial | |
| Japan | S60231696 | TREATMENT FOR CARDIAC DYSFUNCTION | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MAVIK
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0084164 | SPC/GB93/146 | United Kingdom | ⤷ Try a Trial | SPC/GB93/146:, EXPIRES: 20070218 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
